RESUMO
Efficacy, safety, and economical aspects of treatment with abacavir, zidovudine, stavudine, and phosphazide in the schemes of antiretroviral therapy of the HIV-infected patients receiving therapy for hepatitis C virus were tested. Clinical, immunological, and virologic efficacy of treatment and dynamics of hemoglobin, thrombocytes, and alanine aminotransferase as markers of common adverse events recorded at the start of the antiviral therapy of chronic hepatitis C and after 4, 8, 12, 24, 48 weeks of the treatment were evaluated. The usage of these drugs in the schemes of antiretroviral therapy exhibited efficacy, high tolerability and safety for all HIV reverse transcriptase inhibitors.
Assuntos
Didesoxinucleosídeos/uso terapêutico , Infecções por HIV/tratamento farmacológico , Hepatite C Crônica/tratamento farmacológico , Organofosfonatos/uso terapêutico , Inibidores da Transcriptase Reversa/uso terapêutico , Estavudina/uso terapêutico , Zidovudina/análogos & derivados , Zidovudina/uso terapêutico , Adulto , Alanina Transaminase/sangue , Biomarcadores/sangue , Plaquetas/efeitos dos fármacos , Linfócitos T CD4-Positivos/efeitos dos fármacos , Contagem de Células , Coinfecção , Didesoxinucleosídeos/economia , Feminino , Genótipo , Infecções por HIV/sangue , Infecções por HIV/virologia , HIV-1/efeitos dos fármacos , HIV-1/genética , HIV-1/crescimento & desenvolvimento , Hemoglobinas/metabolismo , Hepacivirus/efeitos dos fármacos , Hepacivirus/genética , Hepacivirus/crescimento & desenvolvimento , Hepatite C Crônica/sangue , Hepatite C Crônica/virologia , Humanos , Masculino , Organofosfonatos/economia , Inibidores da Transcriptase Reversa/economia , Estavudina/economia , Zidovudina/economiaRESUMO
AIM: To evaluate the efficacy of boosted darunavir and atazanavir used in antiretroviral therapy (ARVT) regimens for treatment-naïve HIV-infected patients with low baseline immune parameters and a high viral load. MATERIALS AND METHODS: The investigators evaluated the clinical, immunological, and virological efficiency of treatment: the time course of changes in CD4+ lymphocyte levels and viral load at the beginning and at 12, 24, 48, 72, and 96 weeks of antiviral therapy, as well as adverse reactions. RESULTS: The virological effect of once daily darunavir/ritonavir 800/100 mg was highly competitive with that of atazanavir/ritonavir: at 96 weeks of treatment, HIV RNA <120 copies/ml was achieved in 95% of the patients in both treatment groups. A combination of once daily darunavir/ritonavir 800/100 mg ensured a more marked immunological improvement: a difference in the increment (77.1 in 1 µl) of CD4+ lymphocyte count in patients who took darunavir (362.2 in µl) and in those who used atazanavir (285.1 in µl). In the patients who received darunavir, diarrhea, nausea, and headache were observed at the same frequency as in those who had atazanavir. CONCLUSION: The use of the test agents used in the ARVT has shown their efficacy and good tolerability.